Merck Research Laboratories

Latest stories

8d
Irish Central
Interview: How Irish Nobel Prize winner in Medicine ended river blindnessas it had been for generations is due to William “Bill” Campbell, an Irish-born
Interview: How Irish Nobel Prize winner in Medicine ended river blindness
Irish Central / Posted 8 days ago
as it had been for generations is due to William “Bill” Campbell, an Irish-born scientist who, with his colleagues at Merck Research Laboratories, discovered a novel therapy for treating the disease. In 2015, he was awarded the Nobel Prize in... Read more
18d
Business Wire
Results from Merck’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicinepopulations, including those who continue to use illicit drugs,” said Dr. Eliav
Results from Merck’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine
Business Wire / Posted 18 days ago
populations, including those who continue to use illicit drugs,” said Dr. Eliav Barr, vice president, infectious diseases, Merck Research Laboratories. “These findings contribute to the robust body of evidence supporting the efficacy and safety... Read more
21d
Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapythe oncology community, as well as for our head and neck cancer clinical progra
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
Business Wire / Posted 21 days ago
the oncology community, as well as for our head and neck cancer clinical program,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “Together with prior approvals in the treatment of other tumor types, today’s action by the FDA... Read more
24d
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1cancers,” said Dr. Roger Dansey, senior vice president and therapeutic area hea
Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
Business Wire / Posted 24 days ago
cancers,” said Dr. Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. “In the KEYNOTE-010 trial, patients with advanced lung cancer who had failed prior regimens... Read more
28d
Business Wire
Europese Commissie verleent vergunning voor in de handel brengen van MSD ZEPATIER™ (elbasvir/grazoprevir) voor de behandeling van chronische hepatitis C-infectievoor miljoenen mensen die besmet zijn met het hepatitis C-virus genotype 1 of 4
Europese Commissie verleent vergunning voor in de handel brengen van MSD ZEPATIER™ (elbasvir/grazoprevir) voor de behandeling van chronische hepatitis C-infectie
Business Wire / Posted 28 days ago
voor miljoenen mensen die besmet zijn met het hepatitis C-virus genotype 1 of 4,” aldus Dr. Roger M. Perlmutter, President, Merck Research Laboratories, een in de VS gevestigde divisie van Merck & Co., Inc., Kenilworth, NJ, VS. “ZEPATIER is de meest... Read more
24 related stories

People in this news